Citius Pharma's LYMPHIR Secures Broad Payer Coverage, Reports Strong Early Uptake
CTXR sits 45% above its 52-week low of $0.63 on elevated volume (3.5× avg).
Summary
Citius Pharmaceuticals' subsidiary has reported strong early commercial momentum for its LYMPHIR launch, a critical development for the micro-cap company. The report highlights rapid institutional adoption, with 83% of target accounts adding or progressing LYMPHIR through formulary review, and broad payer coverage secured across approximately 135 health plans covering 80% of lives. This positive uptake, marked by sequential growth in orders and no reported reimbursement denials, is highly significant given the company's previously disclosed financial distress and going concern warning. Successful commercialization of LYMPHIR is crucial for Citius Pharmaceuticals to generate revenue and address its financial challenges. Traders will be watching for continued sales growth and future financial updates to assess the long-term impact of this early success.
At the time of this announcement, CTXR was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.1M. The 52-week trading range was $0.63 to $2.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.